Review Article

Dietary treatment of cows’ milk protein allergy in childhood: a commentary by the Committee on Nutrition of the French Society of Paediatrics

C. Dupont1*, J. P. Chouraqui2, D. de Boissieu1, A. Bocquet3, J. L. Bresson1, A. Briend4, D. Darmaun5, M. L. Frelut1, J. Ghisolfi6, J. P. Girardet7, O. Goulet1, R. Hankard8, D. Rieu9, M. Vidailhet10 and D. Turck11

1Service d’Explorations Fonctionnelles Digestives Pédiatriques, Hôpital Necker-Enfants Malades, Université Paris Descartes, 149, rue de Sèvres, 75015 Paris, France
2Université Joseph Fourier, Grenoble, France
3Institut de Pédiatrie et CHU, Besançon, France
4Institut de Recherche sur le Développement, Marseille, France
5Université Paul Sabatier, Toulouse, France
6Université Pierre et Marie Curie, Paris, France
7Université de Poitiers, Poitiers, France
8Université de Montpellier 1, Montpellier, France
9Université Henri Poincaré, Nancy, France
10Université Lille 2, Lille, France

(Received 4 February 2011 – Revised 27 July 2011 – Accepted 1 August 2011 – First published online 25 November 2011)

Abstract

The diagnosis of cows’ milk protein allergy (CMPA) requires first the suspicion of diagnosis based on symptoms described in the medical history, and, second, the elimination of cows’ milk proteins (CMP) from the infant’s diet. Without such rigorous analysis, the elimination of CMP is unjustified, and sometimes harmful. The elimination diet should be strictly followed, at least until 9–12 months of age. If the child is not breast fed or the mother cannot or no longer wishes to breast feed, the first choice is an extensively hydrolysed formula (eHF) of CMP, the efficacy of which has been demonstrated by scientifically sound studies. If it is not tolerated, an amino acid-based formula is warranted. A rice protein-based eHF can be an alternative to a CMP-based eHF. Soya protein-based infant formulae are also a suitable alternative for infants 6 months, after establishing tolerance to soya protein by clinical challenge. CMPA usually resolves during the first 2–3 years. However, the age of recovery varies depending on the child and the type of CMPA, especially whether it is IgE-mediated or not, with the former being more persistent. Once the child reaches the age of 9–12 months, an oral food challenge is carried out in the hospital ward to assess the development of tolerance and, if possible, to allow for the continued reintroduction of CMP at home. Some children with CMPA will tolerate only a limited daily amount of CMP. The current therapeutic options are designed to accelerate the acquisition of tolerance thereof, which seems to be facilitated by repeated exposure to CMP.

Key words: Allergy: Children: Cows’ milk proteins: Diet: Hydrolysates

Cows’ milk protein allergy (CMPA) is defined by the occurrence of clinical symptoms related to the abnormal immune response of the host after ingestion of these proteins. The prevalence of CMPA ranges between 2 and 7%, depending on the methods of recruitment, age distribution of populations studied and diagnostic criteria. The prevalence of a food allergy as perceived by the child’s parents is higher than that of the actual food allergy. Clinical symptoms may affect...
the skin (urticaria, atopic dermatitis), the digestive tract (vomiting, diarrhoea) as well as the respiratory tract (rhinitis, asthma), often combined together and associated with failure to thrive and anaemia, and according to various syndromes corresponding to the immune mechanism, IgE-mediated, non-IgE-mediated, or both. The diagnosis of CMPA, suggested clinically, may be aided by results obtained from skin tests (prick tests), specific IgE assays and/or patch tests, which only indicate sensitisation. The diagnosis requires the elimination–challenge procedure, a standard diagnostic tool for food allergy, without which the elimination diet is unjustified, and sometimes harmful. Confirmation of CMPA will impose the elimination of cows’ milk proteins (CMP) from the patient’s diet. Milk proteins are allergens of animal origin, potentially cross-reacting with the milk of other mammals, and CMP may be the first manifestation of a polysensitisation whereby children may also be allergic to other major allergens, such as soya, egg, peanut or wheat. This explains why the dietary management of CMPA exhibits some uncertainties, difficult to foresee in a given child, and justifying individual and cautious approaches in the introduction of complementary foods. The natural progression of CMPA most often leads to a spontaneous recovery, with a time line that varies from case to case, and which depends mainly on the immunological process (whether IgE-mediated or not), and on the specific type of milk protein involved. The acquisition of oral tolerance and the maintenance thereof seems to be favoured by a regular exposure to the allergens. The dichotomous situation ‘allergic child equals strict diet; cured child equals normal diet’, although still relevant for infants, has been replaced, beyond a certain age, by the concept of ‘dose tolerated by the child’.

The aim of the present review by the Committee on Nutrition of the French Society of Paediatrics (CNFSP) is to clarify the dietary management (with reference to nature, duration, benefits and risks) of CMPA based on the current understanding of this particular allergy, taking into account both the benefits and risks) of CMPA based on the current understanding of the disease and the dietary changes involved.

**Nutritional consequences of cows’ milk protein allergy**

Clinical symptoms of CMPA occur in a child receiving a cows’ milk-based infant formula (IF) and/or dairy products and are very protean, including cutaneous manifestations, digestive manifestations related to ‘gastroenterocolitis’ and ‘enteropathic’ phenomena, as well as respiratory manifestations. Human milk also contains foreign proteins in small amounts, to which some children may react: if allergy symptoms occur in an exclusively breast-fed child, CMPA should be discussed.

The nutritional impact of CMPA varies considerably in both expression and intensity, and should be systematically evaluated. It depends not only on the extent of intestinal mucosal inflammation, which may induce malabsorption and/or protein-losing enteropathy, but on the occurrence of skin protein losses as well, as in the case of atopic dermatitis. Published data do not allow distinguishing between what is related to mucosal inflammation and its consequences, to vomiting or to a decreased dietary intake. Surprisingly, very few studies have addressed Fe deficiency, the most common nutritional deficiency associated with CMPA. Anaemia may not be just a nutritional consequence, but also due to blood loss and, as such, representative of more than just an Fe deficiency. In itself, isolated Fe-deficiency anaemia can reveal CMPA(44).

In an Italian study, 25 % of patients with CMPA were Fe deficient(55). Some cases of infant CMPA manifest themselves in a failure to thrive. The long-term consequences of these nutritional deficiencies are not yet completely known.

**Dietary management of cows’ milk protein allergy before the onset of complementary feeding**

In the case of CMPA, breast-feeding, if still possible, is the first choice. When breast-feeding is not possible or not desired, cows’ milk-based IF should be replaced by a substitute, an extensively hydrolysed formula (eHF) based on the extensive hydrolysis of a source protein, usually from milk, in order to considerably reduce allergenicity, as explained below. eHF are the only formulae suitable to feed infants with documented CMPA and should allow normal growth and development. These eHF are distinct from partially hydrolysed formulae, referred to as ‘hypoallergenic’ in some countries, not suitable for the treatment of CMPA, and to be used only to feed non-breed-fed infants considered to be at risk for allergy(56). However, it should be noted that there are no physical, chemical or immunological criteria that allow any regulatory distinction between a partially hydrolysed formula and an eHF(57).

**Breast-feeding**

When the diagnosis of CMPA is suggested during breast-feeding, a trial elimination diet, with the strict elimination of CMP from the mother’s diet for 2–3 weeks, should result in the prompt disappearance of symptoms in the child(68). The mother should receive daily Ca supplements during the elimination diet. If the elimination diet is ineffective, it should be discontinued, and the possibility of an alternative disease should be examined. If symptoms improve or clear up during the elimination diet, it is then possible to attempt a gradual reintroduction of CMP into the maternal diet that should not exceed the maximal dose tolerated by the child.

When the diagnosis of CMPA is made following the first feeds with cows’ milk-based IF in a breast-fed infant, the continuation of breast-feeding is ideally recommended, without any elimination in the maternal diet since breast milk was previously well tolerated.

**European regulations**

Children with CMPA must be fed with nutritionally adequate hydrolysates in the replacement of cows’ milk-based IF, cows’ milk and dairy products. The composition of the hydrolysates used within the European Union (EU) must meet the requirements of the Commission Directive 1999/21/EC of 25 March 1999 on dietary foods for special medical purposes(59).
The European Commission has limited the content of immunoreactive proteins in the hydrolysates to <1% of the total content of N-containing substances and determines the adequacy and safety of an hydrolysate based on (1) experimental studies (oral administration should not induce sensitisation, in animals, to the intact proteins from which the hydrolysate is manufactured) and (2) clinical trials, showing that the hydrolysate is tolerated by more than 90% of infants presenting with hypersensitivity to the proteins from which the hydrolysate is manufactured.

**Cows’ milk protein hydrolysates**

eHF comply with the European regulations for biological standards and animal testing. Unfortunately, very few clinical studies have confirmed their efficacy in the treatment of CMPA.

eHF available in many European countries (Table 1) are all (except Nutrilon Pepti®, named Galliaigne® in France; Nutricia Advanced Medical Nutrition, Strombeek-Bever, Belgium) lactose-free, and the protein portion consists of either cows’ milk casein hydrolysates (Nutramigen®, and Pregestimil® (Mead Johnson, Evansville, IN, USA), with the same hydrolysed protein, Allernova® (United Pharmaceutical, Paris, France) and Nutriben CMPA® (Madrid Spain)), or cows’ milk whey protein hydrolysates (Pepti-Junior® (Lactalis Nutrition Santé, Laval, France), Alfare® and Althéa® (Nutricia Pepti®). The recommendation made in 1993 by the European Society for Paediatric Gastroenterology and Nutrition, namely to use formulae containing proteins of a molecular weight (MW) of <1300 Da (11), is relevant in terms of quality control (verification of reproducibility among manufacturing processes) but does not allow to predict the degree of immunogenicity or potential reaction in a given child (12). It is noticeable that this 1% threshold of immunoreactive proteins in the hydrolysates, dating back to the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) recommendation of 1999 (12), does not rely on any clinical trials of good scientific quality. Such clinical trials, for which recommendations have been made in 2004 (13), have not yet been performed. Suitable thresholds of reaction, still unknown, however, may be closer to 1/1000 (14).

The MW of peptides and residual allergenicity of the cows’ milk hydrolysates are shown in Table 2, where the lowest residual allergenicity is observed with Nutramigen®, which is lower than that of Alfare®, Peptijunior® and Nutrilon Pepti®, respectively (15–20). Recent modifications of the hydrolysate process (oral administration should not induce sensitisation, in animals, to the intact proteins from which the hydrolysate is manufactured) but does not allow to predict the degree of immunogenicity (verification of reproducibility among manufacturing processes) but does not allow to predict the degree of immunogenicity or potential reaction in a given child (12). It is noticeable that this 1% threshold of immunoreactive proteins in the hydrolysates, dating back to the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) recommendation of 1999 (12), does not rely on any clinical trials of good scientific quality. Such clinical trials, for which recommendations have been made in 2004 (13), have not yet been performed. Suitable thresholds of reaction, still unknown, however, may be closer to 1/1000 (14).

The recently launched eHF Althéa®, with a low peptide MW, identical to the reformulated Alfare®, induced no reaction, similarly to the amino acid-based formula (AAF) reference product in thirty-four infants with CMPA demonstrated by a double-blind, placebo-controlled food challenge (21). A study conducted on Frisolac Allergycare® (Friesland Nutrition, Leeuwarden, The Netherlands), which included twenty-seven children over the age of 1-5 years, showed an efficacy of 75% (30).

The CNFSP regrets the small number of studies and the insufficient statistical power of the few existing studies on cows’ milk protein hydrolysates. Most relevant studies are relatively old and were carried out using product formulations differing from those of currently marketed products. If, based on the experience of most clinicians, these products have been well tolerated by most allergic children, the Committee nonetheless recommends that their compliance with the current efficacy rules expressed in the European regulations be investigated in all.

**Free amino acid-based formulae**

Formulæ based on free amino acids (AAF; Neocate®, Neocate Advance® (Nutricia Advanced Medical Nutrition) after 1 year, Nutramigen AA® (Mead Johnson)) are devoid of intact proteins and peptides. The only traces that may be present in these formulæ would come from contaminants in the starch and lipid parts (including soya in Nutramigen AA®). A systematic review of twenty studies on the use of an AAF (Neocate®) in patients presenting with CMPA concluded as to its efficacy, tolerance and safety (32). When the persistence of symptoms under eHF feeding is suggestive of allergy to eHF, particularly in IgE-mediated gastroenteroprotitis with a failure to thrive or severe atopic eczema, resolution of symptoms and catch-up growth may be obtained with the use of Neocate® (33,34). A study has shown that Nutramigen AA® is efficient and allows normal growth in infants with CMPA (35). However, no data are available in infants with allergy to eHF.

**Rice protein hydrolysates**

Protein hydrolysates not originating from cows’ milk have become available. A prospective study of the tolerance to a

The European Commission has limited the content of immunoreactive proteins in the hydrolysates to <1% of the total content of N-containing substances and determines the adequacy and safety of an hydrolysate based on (1) experimental studies (oral administration should not induce sensitisation, in animals, to the intact proteins from which the hydrolysate is manufactured) and (2) clinical trials, showing that the hydrolysate is tolerated by more than 90% of infants presenting with hypersensitivity to the proteins from which the hydrolysate is manufactured.

**Cows’ milk protein hydrolysates**

eHF comply with the European regulations for biological standards and animal testing. Unfortunately, very few clinical studies have confirmed their efficacy in the treatment of CMPA.

eHF available in many European countries (Table 1) are all (except Nutrilon Pepti®, named Galliaigne® in France; Nutricia Advanced Medical Nutrition, Strombeek-Bever, Belgium) lactose-free, and the protein portion consists of either cows’ milk casein hydrolysates (Nutramigen®, and Pregestimil® (Mead Johnson, Evansville, IN, USA), with the same hydrolysed protein, Allernova® (United Pharmaceutical, Paris, France) and Nutriben CMPA® (Madrid Spain)), or cows’ milk whey protein hydrolysates (Pepti-Junior® (Lactalis Nutrition Santé, Laval, France), Alfare® and Althéa® (Nutricia Pepti®). The recommendation made in 1993 by the European Society for Paediatric Gastroenterology and Nutrition, namely to use formulæ containing proteins of a molecular weight (MW) of <1300 Da (11), is relevant in terms of quality control (verification of reproducibility among manufacturing processes) but does not allow to predict the degree of immunogenicity or potential reaction in a given child (12). It is noticeable that this 1% threshold of immunoreactive proteins in the hydrolysates, dating back to the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) recommendation of 1999 (12), does not rely on any clinical trials of good scientific quality. Such clinical trials, for which recommendations have been made in 2004 (13), have not yet been performed. Suitable thresholds of reaction, still unknown, however, may be closer to 1/1000 (14).

The MW of peptides and residual allergenicity of the cows’ milk hydrolysates are shown in Table 2, where the lowest residual allergenicity is observed with Nutramigen®, which is lower than that of Alfare®, Peptijunior® and Nutrilon Pepti®, respectively (15–20). Recent modifications of the hydrolysate process (oral administration should not induce sensitisation, in animals, to the intact proteins from which the hydrolysate is manufactured) but does not allow to predict the degree of immunogenicity or potential reaction in a given child (12). It is noticeable that this 1% threshold of immunoreactive proteins in the hydrolysates, dating back to the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) recommendation of 1999 (12), does not rely on any clinical trials of good scientific quality. Such clinical trials, for which recommendations have been made in 2004 (13), have not yet been performed. Suitable thresholds of reaction, still unknown, however, may be closer to 1/1000 (14).

The recently launched eHF Althéa®, with a low peptide MW, identical to the reformulated Alfare®, induced no reaction, similarly to the amino acid-based formula (AAF) reference product in thirty-four infants with CMPA demonstrated by a double-blind, placebo-controlled food challenge (21). A study conducted on Frisolac Allergycare® (Friesland Nutrition, Leeuwarden, The Netherlands), which included twenty-seven children over the age of 1-5 years, showed an efficacy of 75% (30).

The CNFSP regrets the small number of studies and the insufficient statistical power of the few existing studies on cows’ milk protein hydrolysates. Most relevant studies are relatively old and were carried out using product formulations differing from those of currently marketed products. If, based on the experience of most clinicians, these products have been well tolerated by most allergic children, the Committee nonetheless recommends that their compliance with the current efficacy rules expressed in the European regulations be investigated in all.

**Free amino acid-based formulae**

Formulæ based on free amino acids (AAF; Neocate®, Neocate Advance® (Nutricia Advanced Medical Nutrition) after 1 year, Nutramigen AA® (Mead Johnson)) are devoid of intact proteins and peptides. The only traces that may be present in these formulæ would come from contaminants in the starch and lipid parts (including soya in Nutramigen AA®). A systematic review of twenty studies on the use of an AAF (Neocate®) in patients presenting with CMPA concluded as to its efficacy, tolerance and safety (32). When the persistence of symptoms under eHF feeding is suggestive of allergy to eHF, particularly in IgE-mediated gastroenteroprotitis with a failure to thrive or severe atopic eczema, resolution of symptoms and catch-up growth may be obtained with the use of Neocate® (33,34). A study has shown that Nutramigen AA® is efficient and allows normal growth in infants with CMPA (35). However, no data are available in infants with allergy to eHF.

**Rice protein hydrolysates**

Protein hydrolysates not originating from cows’ milk have become available. A prospective study of the tolerance to a
Table 1. Extensively hydrolysed formulae (eHF) and amino acid (AA)-based formulae (AAF) available in Europe for children with cows’ milk protein allergy*

<table>
<thead>
<tr>
<th>Mean concentration (per 100 ml)</th>
<th>Nutramigen 1 LGG&lt;sup&gt;®&lt;/sup&gt; (Mead Johnson)</th>
<th>Pregestimil&lt;sup&gt;®&lt;/sup&gt; (Mead Johnson)</th>
<th>Aflone® (Nestlé)</th>
<th>Almova AR&lt;sup&gt;®&lt;/sup&gt; (Novalac)</th>
<th>Nutriben CMPA&lt;sup&gt;®&lt;/sup&gt; (Nutriben)</th>
<th>Pepti-Junior 1&lt;sup&gt;®&lt;/sup&gt; (Lactalis Nutrition &amp; Santé)</th>
<th>Nutrition Pepti 1&lt;sup&gt;®&lt;/sup&gt; (Nutricia Advanced Medical Nutrition)</th>
<th>Blemil plus Arroz 1&lt;sup&gt;®&lt;/sup&gt; (Ordesa)</th>
<th>Nutramigen AA&lt;sup&gt;®&lt;/sup&gt; (Mead Johnson)</th>
<th>Neocate&lt;sup&gt;®&lt;/sup&gt; (Nutricia Advanced Medical Nutrition)</th>
<th>Neocate Advance&lt;sup&gt;®&lt;/sup&gt; (Nutricia Advanced Medical Nutrition)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Source of information eHF or AAF</td>
<td>Company Casein eHF, supplemented with AA</td>
<td>Company Casein eHF, supplemented with AA</td>
<td>Company Whey eHF†</td>
<td>Company Casein eHF</td>
<td>Company Labelling Casein eHF</td>
<td>Company Whey eHF</td>
<td>Company Whey eHF</td>
<td>Company Rice protein eHF, supplemented with AA</td>
<td>Company AAF</td>
<td>Company AAF</td>
<td>Company AAF</td>
</tr>
<tr>
<td>Energy (kJ)</td>
<td>284.5</td>
<td>297.1</td>
<td>279.5</td>
<td>280.3</td>
<td>276.1</td>
<td>276.1</td>
<td>284.5</td>
<td>284.5</td>
<td>297.1</td>
<td>418.4</td>
<td></td>
</tr>
<tr>
<td>Proteins (g)</td>
<td>1.9</td>
<td>2.1</td>
<td>1.6</td>
<td>1.6</td>
<td>1.8</td>
<td>1.6</td>
<td>1.6</td>
<td>1.8</td>
<td>1.9</td>
<td>2.5</td>
<td></td>
</tr>
<tr>
<td>Carbohydrates (g)</td>
<td>7.5</td>
<td>6.9</td>
<td>7.1</td>
<td>7.1</td>
<td>7.2</td>
<td>6.8</td>
<td>7.1</td>
<td>7.6</td>
<td>7</td>
<td>14.6</td>
<td></td>
</tr>
<tr>
<td>Lactose (g)</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>2.6</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>Maltodextrins (g)</td>
<td>6</td>
<td>4.7</td>
<td>6.7</td>
<td>4.6</td>
<td>5.7</td>
<td>4.3</td>
<td>6</td>
<td>6.3</td>
<td>6.4</td>
<td>11.8</td>
<td></td>
</tr>
<tr>
<td>Starch (g)</td>
<td>1.5</td>
<td>0.85</td>
<td>2.5</td>
<td>1.6</td>
<td>0.7</td>
<td>0.7</td>
<td>0.7</td>
<td>0.7</td>
<td>0.7</td>
<td>0.7</td>
<td></td>
</tr>
<tr>
<td>Type</td>
<td>Maize</td>
<td>Maize</td>
<td>Potato</td>
<td>Maize</td>
<td>Glucose syrup</td>
<td>Maize</td>
<td>Maize</td>
<td>Tapioca</td>
<td>Maize</td>
<td>Maize</td>
<td></td>
</tr>
<tr>
<td>Others (g)</td>
<td>Glucose 0.7</td>
<td>Maltodextrin 0.13</td>
<td>1</td>
<td>0.6</td>
<td>1.5</td>
<td>2.8</td>
<td>3.5</td>
<td>3.5</td>
<td>4.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lipids (g)</td>
<td>3.4</td>
<td>3.8</td>
<td>3.5</td>
<td>3.5</td>
<td>3.5</td>
<td>3.5</td>
<td>3.5</td>
<td>3.5</td>
<td>3.5</td>
<td>3.5</td>
<td></td>
</tr>
<tr>
<td>Linoleic acid (mg)</td>
<td>610</td>
<td>760</td>
<td>608</td>
<td>429</td>
<td>476</td>
<td>463</td>
<td>444</td>
<td>580</td>
<td>579</td>
<td>380</td>
<td></td>
</tr>
<tr>
<td>α-Linolenic acid (mg)</td>
<td>54</td>
<td>54</td>
<td>64.4</td>
<td>60</td>
<td>88</td>
<td>85</td>
<td>38</td>
<td>54</td>
<td>57.9</td>
<td>94</td>
<td></td>
</tr>
<tr>
<td>Linoleic acid/α-linolenic acid ratio</td>
<td>11.3</td>
<td>14.1</td>
<td>7.9</td>
<td>10.0</td>
<td>7.2</td>
<td>5.4</td>
<td>5.4</td>
<td>11.7</td>
<td>10.7</td>
<td>10.0</td>
<td>4.0</td>
</tr>
<tr>
<td>Arachidonic acid (mg)</td>
<td>23</td>
<td>23</td>
<td>0</td>
<td>0</td>
<td>6.7</td>
<td>6.7</td>
<td>0</td>
<td>23</td>
<td>11.3</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>DHA (mg)</td>
<td>11.6</td>
<td>11.6</td>
<td>0</td>
<td>0</td>
<td>6.7</td>
<td>6.7</td>
<td>0</td>
<td>11.5</td>
<td>6.4</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Medium-chain TAG (%)</td>
<td>12</td>
<td>55</td>
<td>39</td>
<td>39</td>
<td>1</td>
<td>51</td>
<td>20</td>
<td>12</td>
<td>35</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Probiotics</td>
<td>Lactobacillus rhamnosus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ca (mg)</td>
<td>64</td>
<td>78</td>
<td>54</td>
<td>70.2</td>
<td>67</td>
<td>49.9</td>
<td>68</td>
<td>61</td>
<td>64</td>
<td>69</td>
<td>50.0</td>
</tr>
<tr>
<td>P (mg)</td>
<td>53</td>
<td>51</td>
<td>36.2</td>
<td>45.9</td>
<td>43</td>
<td>27.6</td>
<td>34</td>
<td>34</td>
<td>35</td>
<td>50</td>
<td>39.0</td>
</tr>
<tr>
<td>Fe (mg)</td>
<td>1.22</td>
<td>1.22</td>
<td>0.7</td>
<td>0.8</td>
<td>0.8</td>
<td>1</td>
<td>0.7</td>
<td>1.22</td>
<td>1.05</td>
<td>0.62</td>
<td></td>
</tr>
<tr>
<td>Osmolarity (mOsmol/l)</td>
<td>260</td>
<td>300</td>
<td>194</td>
<td>218</td>
<td>185</td>
<td>190</td>
<td>248</td>
<td>200</td>
<td>312</td>
<td>320</td>
<td>520</td>
</tr>
</tbody>
</table>

* Based on products also available in France; only infant formula (0–6 months) when applicable.
† Hydrolysate identical to that of Althera®.

C. Dupont et al.
British Journal of Nutrition
Downloaded from https://www.cambridge.org/core. IP address: 54.70.40.11, on 07 Apr 2019 at 23:14:44, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114511004831
British Journal of Nutrition

CMPA, cows’ milk protein allergy; IgE-m, IgE-mediated; P, prospective; R, randomised; DB, double blind; multi-A, multi-allergic; O, open; B, blind; CO, cross-over.

Table 3. Analysis of clinical studies assessing the efficacy of extensive protein hydrolysates: percentage of patients with no reaction during different evaluation tests (clinical symptoms, skin prick tests (SPT), oral food challenge (OFC) and RAST)

<table>
<thead>
<tr>
<th>Author (year)</th>
<th>Type of CMPA</th>
<th>Age (months)</th>
<th>Type of study</th>
<th>Tests</th>
<th>Cases</th>
<th>Product</th>
<th>Efficacy (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Høst(22) (1988)</td>
<td>IgE-m</td>
<td>12–40</td>
<td>P, R, DB</td>
<td>SPT 5</td>
<td>Nutramigen©</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Sampson(23) (1991)</td>
<td>IgE-m</td>
<td>8–114</td>
<td>P, DB</td>
<td>SPT 10</td>
<td>Nutramigen©</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>Wahn(17) (1992)</td>
<td>IgE-m</td>
<td>5–114</td>
<td>P, O</td>
<td>RAST* 10</td>
<td>Nutramigen®</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Dean(27) (1993)</td>
<td>IgE-m</td>
<td>7–288</td>
<td>P, O</td>
<td>RAST* 15</td>
<td>Nutramigen®</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Halken(28) (1993)</td>
<td>IgE-m 10 non-IgE-m</td>
<td>1–12</td>
<td>P, O</td>
<td>Follow-up 16</td>
<td>Nutramigen®</td>
<td>100</td>
<td></td>
</tr>
<tr>
<td>Terheggen-Lagro(30) (2002)</td>
<td>IgE-m</td>
<td>1,5–14,8</td>
<td>P, R, DB, CO</td>
<td>Follow-up 27</td>
<td>Nutramigen®</td>
<td>100</td>
<td></td>
</tr>
</tbody>
</table>

Soya protein-based infant formulae

Soya protein-based IF are dietary products without CMP, enriched in methionine, carnitine, Fe and Zn. They contain phytates, Al and high amounts of phyto-oestrogens, the potential effects of which are still poorly understood in children. Infants with CMPA may also be allergic to soya protein. This association was observed in one study in 14% of children aged 3–41 months presenting with IgE-mediated CMPA, and 10% in another study, with little difference between IgE-mediated and non-IgE-mediated CMPA, but with a higher prevalence among infants under 6 months of age. Soya protein-based IF are not indicated in the treatment of infants with CMPA below 6 months of age, owing to a high level of phytates and a high phyto-oestrogen intake resulting from exclusive formula feeding.

Inappropriate products

The composition (i.e. in terms of protein, fat, folic acid and mineral content) of milk from other mammals (goat, sheep, etc.) may also be allergenic. Infant formulae based on milk from other mammals should be avoided in the treatment of infants with CMPA.
donkey, horse, etc.) makes them nutritionally unsuitable when they are the only food provided to infants, whether the infant is allergic or not.

Industrial juices made of soya, rice, almond, coconut or chestnut are improperly called ‘milks’ and usually sold in organic outlets. They are totally unsuitable to meet infant nutritional needs and should therefore not be used. Severe nutritional disorders, such as kwashiorkor\(^{(43)}\) and rickets\(^{(2,44,45)}\), have been described in infants with CMPA fed such an inappropriate elimination diet.

### Recommendations for the use of hydrolysates by expert committees and scientific societies

Recommendations for the use of hydrolysates in CMPA are limited. The choice of a hydrolysate varies from one country to another or within the same country. A recent paper describing the identification and management of CMPA depicts all the eHF available for children in the UK\(^{(46)}\).

An international working group has released draft recommendations for the management of CMPA in infants, whether breast fed or not. In case of suspicion of CMPA, the group recommends using an eHF based on soluble protein or casein; in severe cases (either where there is a life-threatening risk or a severe failure to thrive), the recommendation is to readily use an AAF\(^{(47)}\).

A group of Australian experts suggests eHF as the first resort in infants under 6 months of age, in cases where a current allergy exists, and in cases concerning gastrointestinal symptoms and atopic dermatitis. The group recommends soya protein-based IF in infants over 6 months with presently existing reactions to CMP, and in the case of gastrointestinal symptoms or atopic dermatitis with normal growth. In the case of anaphylaxis, the group recommends AAF as a first choice, until allergic tests have been performed, in order to avoid any severe reaction to an eHF\(^{(47,48)}\).

In 2006, the Committee on Nutrition of the ESPGHAN recommended using eHF in cases of proven CMPA in infants and avoiding soya protein-based IF before the age of 6 months. Once the infant has reached the age of 6 months, if soya protein-based IF have been proposed because of their lower cost and greater acceptability, a test of clinical tolerance to soya protein should be performed first\(^{(59)}\). In 2008, the American Academy of Pediatrics recommended the use of eHF as a first choice in the case of proven CMPA and of AAF in the case of a failure of eHF\(^{(49)}\).

### Reimbursement of extensively hydrolysed formula and amino acid-based formula

The cost of formulae to be used during CMPA is as follows: AAF > milk eHF > rice eHF > soya protein formulae. Cows’ milk- and rice-based eHF (where they are available) are usually sold in pharmacies. From a family point of view, the cost largely depends on the reimbursement rate by the health care system, with great variations from one country to another within the EU.

### Introduction of complementary feeding in patients with cows’ milk protein allergy

#### Milk-derived products and bovine meat

When the diagnosis of CMPA is made, the CMP elimination diet should be carefully explained to parents. It excludes not only milk, but also dairy products, cheese, butter, cream and all industrial products containing milk. The presence of CMP is normally mentioned on a product label in the following terms: cows’ milk proteins; casein; caseinates; whey; lactalbumin; serum albumin. Within the EU, this labelling must be in compliance with the Directive 2003/89/EC amending Directive 2000/13/EC with regard to indication of the ingredients present in foodstuffs\(^{(49)}\).

Children allergic to bovine serum albumin, i.e. 13–20% of cases of CMPA, are generally allergic to beef and veal meat as well\(^{(50)}\). The practice of excluding beef and veal is thus not systematically used in the treatment of CMPA. In the absence of diagnostic tests (skin tests or RAST), it is logical to avoid these meats during the diagnosis elimination diet and test their tolerance thereafter.

Lactose is not, in theory, contraindicated in the diets of children with CMPA. However, lactose used in the food industry may, depending on its degree of purification, contain significant traces of CMP, sometimes responsible for allergic reactions, which has led some authors to consider it to be inappropriate when used in food to be consumed by children with CMPA\(^{(21)}\). The reaction to CMP traces (up to 2%) in ‘drug’ grade lactose is also possible\(^{(51)}\). Similarly, allergic individuals may react to CMP contaminants after the ingestion of probiotics raised on lactose or milk\(^{(52,53)}\).

As IgE antibodies are directed primarily against conformational epitopes that are largely destroyed by heat, heat treatment might improve tolerance to milk and dairy products, as is observed with egg\(^{(54)}\). In a recent survey, the majority (75%) of a cohort of 100 allergic children, with a mean age of 7.5 years (range 2–17.3 years), tolerated products containing milk baked in the oven, i.e., in practice, cakes and pastries\(^{(55)}\). The likelihood of such tolerance among younger children, and indeed for all cases of CMPA, is unknown. Moreover, in mice, pasteurisation of CMP seems to facilitate allergic sensitisation by enhancing the uptake of CMP by Peyer’s patches\(^{(56)}\).

#### Soya

After 6 months of age, and subject to prior verification of clinical tolerance, soya protein follow-on formulae and everyday soya foods can be used in complementary feeding. As stated above, such foods are tolerated by most children with CMPA.

#### Goats’ and ewes’ milk

Goats’ and ewes’ milk (fermented or not), cheeses and desserts provide a real benefit in terms of Ca intake, if tolerance to cows’ milk has not been acquired after 1 year of age. However, goat’s and ewe’s milk proteins may cross-react with CMP
in patients with CMPA, and the tolerance thereof will depend on individual susceptibility\(^{(57)}\).

Some studies have suggested the feasibility of recipes aimed at replacing IF based on cows' milk or soya, including the use of chicken or lamb as a protein source, with good results in terms of acceptability, tolerance and growth\(^{(58,59)}\). Cantani\(^{(60)}\) also demonstrated the feasibility of an 'oligo-antigenic' diet (the so-called 'Rezza diet'), based on meat, and which excludes the consumption of milk, egg, wheat or peanut products. Such diets have no place in countries where adequate substitutes are available.

### Reading the labels and home-cooking

Access to product information from companies is regulated in the EU legislation (http://eur-lex.europa.eu/) by the Labelling Directive (Directive 2000/13/EC) and its later amendments that specifically refer to allergenic foods and require manufacturers to declare all ingredients, including milk or dairy products, present in pre-packaged foods sold in the EU. This directive has been amended several times with regard to allergens. The Directive 2003/89/EC introduced Annex IIa, a list of allergenic foods that must always be labelled when present in a product and the Directive 2007/68/EC, which has the most recent amendment of Annex IIa, lists all the allergenic foods that must be labelled as well as a few products derived from these foods for which allergen labelling is not required. The European Food Safety Authority website also provides information on food allergen labelling in Europe (http://www.efsa.europa.eu/).

Milk-free products are more and more available in common retail outlets but still appear mostly in organic retail outlets, where parents usually get both the products and the dietary advice. A major issue for parents is the cooking of milk-free dishes, and their ability to use, in this preparation, the replacement formulae, based on their organoleptic properties and their ability to lend themselves to preparation of foods for infants.

### Nutritional consequences of elimination diets

#### Nutritional risks

Elimination diets prevent the allergic inflammation induced by the offending food, but may have deleterious effects on the child's nutritional status and growth pattern. It is essential to monitor the elimination diet in order to ensure adequate intake of essential nutrients. Undernutrition may be the consequence of an uncontrolled, inappropriate and/or excessively strict elimination diet\(^{(59)}\).

Nutritional risk is higher in the case of multiple food allergies: the elimination diet may easily result in deficiencies, especially if it includes multiple exclusions. Exclusion of foods such as egg and fish may cause a deficiency in \(\omega-3\) long-chain PUFA\(^{(61)}\). In a study conducted by Christie et al\(^{(62)}\), children with at least two food allergies were slightly shorter (height-for-age percentile) than those with a single food allergy \((P<0.05)\). Also, more than 25% of children consumed less than two-thirds of the dietary reference intakes for Ca, vitamin D and vitamin E. The low Ca intake was especially marked in children with CMPA or multiple allergies.

The nutritional risks seem also to increase when CMPA is associated with asthma. Children suffering from a CMPA associated with asthma, for more than 4 years, and who were treated with corticosteroids, ingested only 25% of the dietary reference intakes of Ca; accordingly, their height, bone mineral content, bone mineral density and bone age were below that of the reference population\(^{(63)}\).

#### Nutritional efficacy of substitute formulae

The ESPGHAN published in 2001 recommendations and comments on the nutritional and safety assessment of breast milk substitutes and other dietary products for infants for long- and short-term outcomes, and encouraged health care providers to promote the incorporation of these principles into their national regulatory processes\(^{(64)}\). Only a few formulae marketed in Europe have been subject to studies evaluating adequately their nutritional efficacy (Nutramigen\(^{®}\), Pregestimil\(^{®}\), Neocate\(^{®}\), Nutramigen AA\(^{®}\), Blemil Arroz\(^{®}\) (Ordesa, Barcelona, Spain), Althéra\(^{®}\)).

Healthy infants fed with casein-based eHF (including Nutramigen\(^{®}\)) had a poorer Fe status and an excessive amino acid intake, resulting in a rise in blood urea N and plasma amino acids, compared with infants fed with a standard formula, warranting both reducing and balancing the amino acid composition of some formulae\(^{(65)}\). In children with CMPA fed Althéra\(^{®}\) for 6 months, length and head circumference were similar to Euro-growth standards, but weight was slightly lower, similarly to the comparator Neocate\(^{®}(21)\).

In Finnish children with proven CMPA, and fed from 7.5 months with a soya protein follow-on formula or with a soluble protein-based eHF (PeptidTuttil\(^{®}\), Valio Limited, Helsinki, Finland), often supplemented with Ca and vitamin D, growth and nutritional status were adequate\(^{(66)}\).

Infants (\(n=58\) with confirmed CMPA-related atopic dermatitis were given openly either a rice-based eHF supplemented with lysine and threonine, a soya protein-based IF or a casein-based eHF and compared with an unrestricted diet in the absence of CMPA (\(n=30\))\(^{(67)}\). The mean weight/age Z score at 2 years of age was similar in the three CMPA groups, but lower with the rice-based eHF diet than with the unrestricted diet during the periods between 9–12 months and 12–18 months, i.e. after the start of complementary feeding. Healthy infants fed for 16 weeks with a rice-based eHF diet supplemented with lysine and threonine (\(n=32\) or with a cows' milk-based IF (\(n=33\) had comparable normal growth and biochemical parameters\(^{(68)}\). Infants breast fed for at least 4 months (\(n=95\)) and suffering from CMPA were either breast fed until 12 months of age or randomly weaned at 5–6 months of age to either a soya protein-based IF, a casein-based eHF or a rice-based eHF\(^{(69)}\). Weight/age and height/age Z scores were below the mean at 6 months of age in all groups, probably due to CMPA. With the rice-based eHF, the height/age Z score was identical to that of the soya group and the breast-fed group at 9 and
12 months. A rice-based eHF enriched with lysine, threonine and tryptophan was compared with a casein-based eHF in eighty-one infants with CMPA and a mean age of 4 months\((35)\). Infants with a baseline weight lower than average normalised their weight by 12 months of age using the rice-based eHF \(v\). 18 months using the casein-based eHF. The growth pattern during breast-feeding or feeding with hydrolysates has been nicely investigated in the German Infant Nutritional Intervention (GINI) study\((70)\): feeding with a casein-based eHF (Nutramigen\(\text{®}\)) induced a transient reduction in weight gain during the first year of life, without long-term consequences on BMI\((71)\).

Several clinical trials have shown that Neocate\(\text{®}\) ensured normal growth in the case of an allergy to eHF and in the case of multiple food allergies, as well as a growth pattern identical to that obtained with eHF when they are well tolerated\((32–34)\). Another study has also shown that growth obtained with Nutramigen AA\(\text{®}\) in children presenting CMPA is comparable with that obtained with Nutramigen\(\text{®}\), a casein-based eHF\((35)\).

The CNSFP regrets that all hydrolysates available on the European market have not been subject to a detailed assessment of their nutritional efficacy, in accordance with the regulations.

**Addition of compounds presumed to be active on the allergy**

The use of compounds presumed to be active on the immunological reaction, in addition to the milk substitute, should be considered with great caution in the current state of evidence. The putative interest of some probiotics has been suggested, but there is currently no evidence that probiotics can be helpful in the treatment of a child with CMPA\((72)\). A recent study has argued against the efficacy of probiotics (Lactobacillus casei and Bifidobacterium lactis Bb CR431-12) in the process of tolerance acquisition\((75)\). There is no study demonstrating the effectiveness of long-chain-PUFA in the treatment of CMPA.

**Duration of the elimination diet**

**Variable duration and frequent incomplete recovery from a cows’ milk protein allergy**

It can take as long as between 2 and 4 weeks for the symptoms of an infant who suffers from a CMPA to disappear, when following an elimination diet\((8)\). The evolution of the CMPA when treated with an elimination diet is usually towards spontaneous remission, more or less in parallel with the evolution of biological tests, albeit that it is sometimes slow and incomplete\((71–79)\). According to Høst et al.,\((77)\) remission rates are 45–50 % at 1 year, 60–75 % at 2 years and 85–90 % at 3 years (with an associated food allergy in 50 % of the cases). In the study by Carroccio et al.,\((78)\) remission rates are lower, at 30, 54 % and 70 % at 1, 2 and 3 years, respectively. Persistent cases of CMPA are characterised by (1) the intensity of the familial atopic disease, (2) a longer period between the consumption of the CMP and the onset of symptoms, (3) a high frequency of multiple food allergy and allergic diseases\((76)\) and (4) an allergy to casein more than to soluble proteins.

CMPA with early gastrointestinal symptoms has a better prognosis\((35)\). CMPA with IgE-mediated symptoms is associated with an increased risk of persistence, development of reactions to other foods and the occurrence of asthma and rhino-conjunctivitis later in childhood\((77,78)\). In a study by Saarinen et al.\((79)\), 15 % of children with IgE-mediated CMPA had persistent symptoms after the age of 8–6 years, while patients with non-IgE-mediated CMPA were all free of disease by the age of 5 years. In another study by Skripak et al.\((80)\), spontaneous resolution of IgE-mediated CMPA occurred in 19 % of children at 4 years, 42 % at 8 years and 79 % at 16 years. Patients with persistent allergy had the highest levels of specific IgE. The coexistence of asthma and allergic rhinitis is a factor that presents a poor prognosis.

It is common for a CMPA to be resolved, but this resolution is not always complete. According to Kokkonen et al.\((81)\), some children considered to be free of CMPA may retain a ‘residual disease’ and may not be able to tolerate a ‘normal’ intake of milk and dairy products. At the age of 10 years, 45 % of children, who were reliably diagnosed with a CMPA during the first year of life and who have since been considered free of that CMPA, complained of gastrointestinal symptoms (diarrhoea, abdominal pain and/or nausea) in relation to the ingestion of dairy products, \(v\). 10 % in the control group. The prevalence of lactose intolerance during the hydrogen breath test was 14 % in CMPA children, \(v\). 3 % in the control group. In addition, ‘incomplete recovery’ encompasses cases where the loss of symptoms is accompanied by persistent sensitisation, which may explain some intriguing issues such as recurrence of symptoms during intercurrent illnesses or during pregnancy and lactation. Noticeably, these situations may be encountered in parents of children being taken care of with CMPA, albeit with no studied frequency at the moment.

The required duration of the strict elimination diet cannot be clearly established \(a\ priori\) for a given individual. In practice, however, an early case of CMPA that is non-IgE-dependent, and which presents with predominantly digestive manifestations, may only last for a short period of time, and may warrant a review with further tests at the age of 9 months\((35)\). However, where there is a later onset of CMPA, which is IgE-dependent, and which presents with skin manifestations among others, there is the possibility that this type of allergy could last longer and should not require further evaluation before the age of 1 year\((79,80)\).

**Milk, oral food challenge and the adaptation of the duration and nature of the elimination diet for the individual**

A decision on whether to discontinue the elimination diet should be made with reference to an oral food challenge (OFC) or provocation test on cows’ milk, which should be performed in the hospital day care unit, and followed by the gradual reintroduction of milk and dairy products at home.
The protocol for such reintroduction should be discussed, particularly where a severe reaction is anticipated\(^{82–85}\). IgE-mediated CMPA carries the risk of an anaphylactic shock to milk. Some cases of non-IgE-mediated CMPA, such as enterocolitis induced by food proteins, carry the risk of dehydration from diarrhoea and vomiting within 5–6 h after the start of the test, which may require parenteral rehydration\(^{90}\).

According to a group of international experts, 'the test must be carried out in a hospital in an area equipped for severe reactions, close to an intensive care unit, by a medical personnel and paramedics used to carry out these tests\(^{87}\). Information to patients and their families and informed consent are essential. The physician must be present on site and nurses must be experienced and able to detect adverse reactions. A day of hospitalisation is usually sufficient. However, monitoring during at least 4 h after administration of the last dose is recommended to cover the period of severe and immediate reactions and allow the diagnosis of delayed reactions. The occurrence of a reaction can lead to a conventional hospitalisation for observation. For delayed symptoms such as eczema, the OFC can start in a hospital setting but may be continued outside the hospital after returning home'. The CNSFP adds the following comments: most children with non-IgE-mediated CMPA do not need day-care admission, since they are not at risk of anaphylactic shock. Some of them, however, exhibit a food protein-induced enteropathy syndrome, a non-IgE-mediated disorder, which puts them at risk of dehydration during the 4 h following the end of the OFC. If a child had an inadvertent milk challenge (e.g. a glass of milk at a friend’s house) and it is clear from the medical history that no reaction occurred, admitting the child to hospital for a similar challenge does not seem worthwhile.

Following the OFC, the progressive reintroduction of CMP continues at home. The clinical response to CMP may occur up to 1 month after the commencement of the OFC\(^{90}\). This progressive reintroduction at home allows determining the CMP dose that the child is able to tolerate. This dose may correspond to the usual intake of milk and dairy products in a Western diet or be more limited in children who continue to suffer from the ‘residual disease’\(^{91}\). The current state of the research does not allow to say what proportion of children whose OFC has demonstrated the consumption of a quantity of milk equivalent to one bottle, without difficulty, will retain a limited long-term tolerance to dairy products. The persistence of clinical symptoms suggestive of the recurrence of a CMPA during the gradual increase of CMP intake at home does not ipso facto warrant a return to the strict exclusion of CMP. Indeed, several recent studies have indicated that the continued presence of CMP in the diet at a tolerated dose facilitates the acquisition of a long-term tolerance\(^{90,95}\). The increase in food diversity allowed into the diet also makes social life easier. Such management requires a full education and the active participation of parents, and is not always feasible. It is facilitated by the knowledge of the protein concentrations in the dairy products available (Table 4).

In conclusion, although the spontaneous resolution of CMPA is common, it is not always complete, as children often spontaneously limit their intake of milk products to the tolerated dose, i.e. the dose for which ingestion does not trigger symptoms. The regular encounter with the allergen at a low dosage could facilitate the acquisition of a tolerance towards the allergen. Once tolerance is attained, the regular intake of the allergen is necessary in order to maintain that tolerance.

**Progressive normalisation of diet: difficulties in acceptability**

The prevalence of food neophobia, i.e. the refusal by children to eat new food, known to be a normal phenomenon between 2 and 10 years of age, seems to be more common or pronounced when an elimination diet has been imposed by a food allergy. An evaluation using a standardised scale of food neophobia and a familiar food questionnaire showed that children with a personal history of allergy (mean age 7 years, 2 months) were more reluctant to try new foods than their non-allergic sibling (average age 9 years, 5 months)\(^{90}\). Several factors may increase neophobia: the severity of the symptoms, the duration of the delay in diagnosis, the difficulty of the elimination diet and the monotony of meals.

**Tolerance induction and immunotherapy (in specialised units)**

The induction of tolerance aims at ‘forcing’ a lack of tolerance of CMP, starting with very low doses, increased very gradually to induce ‘desensitisation’\(^{91}\). The term ‘immunotherapy’ is

<table>
<thead>
<tr>
<th>Food</th>
<th>Serving</th>
<th>Proteins (g)</th>
<th>Equivalence in amount of milk (ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cows’ milk</td>
<td>100 ml</td>
<td>3·2</td>
<td>100</td>
</tr>
<tr>
<td>Plain yogurt</td>
<td>125 ml</td>
<td>5·4</td>
<td>168</td>
</tr>
<tr>
<td>Plain petit-suisse (white cheese, 40 % fat)</td>
<td>60 g</td>
<td>5·6</td>
<td>175</td>
</tr>
<tr>
<td>Flavoured petit-suisse</td>
<td>50 g</td>
<td>3·2</td>
<td>100</td>
</tr>
<tr>
<td>Soft white cheese (20 % fat)</td>
<td>100 g</td>
<td>7·0</td>
<td>200</td>
</tr>
<tr>
<td>Butter</td>
<td>100 g</td>
<td>0·7</td>
<td>21·8</td>
</tr>
<tr>
<td>Fresh cream</td>
<td>100 g</td>
<td>2·2</td>
<td>68·7</td>
</tr>
<tr>
<td>Emmental, Comté, Gruyère</td>
<td>30 g</td>
<td>9</td>
<td>280</td>
</tr>
<tr>
<td>Camembert (1/8)</td>
<td>31 g</td>
<td>6·6</td>
<td>206</td>
</tr>
<tr>
<td>Melted cheese (serving)</td>
<td>15 g</td>
<td>2·5</td>
<td>78</td>
</tr>
<tr>
<td>Fermented milk</td>
<td>93·7 ml</td>
<td>2·7</td>
<td>84</td>
</tr>
</tbody>
</table>
probably more appropriate; immunotherapy leads to either a ‘tolerance’, the final state of non-reactivity to the allergen independent of its regular use, whereas ‘desensitisation’ simply increases the threshold of reactivity. The technique of Meglio et al.\(^{(92)}\), studied in twenty-one children with IgE-mediated CMPA persisting beyond the age of 5 years, i.e. with a low chance of spontaneous recovery, consisted of administering a very low initial dose of milk (a drop of milk diluted to 1/25th), which was subsequently doubled every 7 d. After 6 months, fifteen children tolerated a daily dose of 200 ml of milk, three a dose between 40 and 80 ml and three retained allergic reactions even to small doses. In a randomised study of this ‘oral tolerance’ protocol in ninety-seven children over 5 years of age and suffering from severe CMPA, 36% of treated children achieved complete tolerance after 1 year, 54% became partially tolerant (5–150 ml milk/d) and 10% did not complete the protocol because of respiratory or gastrointestinal manifestations, while none of the children became tolerant in the control group\(^{(93)}\). A protocol of ‘oral tolerance’ in thirty children, who suffered from a CMPA and had an average age of 8 years, allowed 23% of children to tolerate a normal diet after 1 year, 13% to tolerate a milk intake ≥ 150 ml/d and 54% to exhibit a partial tolerance, while 10% dropped out of the protocol for adverse effects, and no improvement was observed in thirty untreated controls\(^{(94)}\). The maintenance of a tolerance requires the body to be regularly exposed to the allergen, as is confirmed by other studies\(^{(95)}\). This technique has the major advantage of substantially reducing the risk of severe reactions after accidental ingestion of the allergen\(^{(96)}\).

Sublingual desensitisation is a technique used in the realm of respiratory allergies and can be adapted to be used in the assessment of food allergies. A study of this type, on patients with persistent CMPA, was carried out using half-skimmed milk placed under the tongue every day for 2 min before breakfast, at an initial dose of 0.1 ml, increased by 0.1 ml every 15 d, and reaching a dose of 1 ml. The OFC showed an increase in the milk dose inducing a reaction after 6 months, and the diet could be normalised in 50% of patients\(^{(97)}\). This technique appears to reduce the risk of accidental allergic reactions to small amounts of milk or even to cure some children; it is simple to perform and without serious adverse effects, but its benefit must be confirmed in randomised studies to determine the amount of milk to use and the time required to optimise the results.

It is also possible to envisage the use of a patch as a desensitisation technique, and an initial study has analysed its safety, tolerance and potential benefits\(^{(98)}\).

Management by parents and at school

**Parental information**

Providing information to parents at the different stages of the disease management is crucial, especially to facilitate the dialogue with the various settings that accommodate the allergic child, such as the school\(^{(99)}\). A Swedish study has reported a method of group therapeutic education in a paediatric health centre\(^{(100)}\). It must be emphasised that the initiation of an elimination diet, which is consistent with the recognition of a risk resulting from the accidental ingestion of dairy products, must be accompanied by a thoughtful consideration of the conditions of implementation of treatment with epinephrine in situations of a possible anaphylactic shock or acute laryngeal oedema. The modalities of implementing such constraints are now facilitated by self-injection pens, the use of which can be considered in the scenarios published in 2005\(^{(101)}\).

**Management at school**

Children with CMPA should be able to attend school and follow their educational curriculum or be accommodated in the community while adhering to their elimination diet. In practice, the school doctor’s mission is to establish a ‘contract’ between the family, on the one hand, and the school authorities (the educational team, the authorities responsible for school lunches), on the other hand.

**Recommendations and statements**

In the current state of knowledge, and based on the analysis of the literature presented in the present review, the CNFSP makes the following recommendations and statements, which are briefly summarised in Fig. 1.

**Diagnosis of cows’ milk protein allergy**

The diagnosis of CMPA requires first the suspicion of diagnosis based on symptoms described in the medical history, and, second, the elimination of CMP from the infant’s diet. Without such rigorous analysis, the elimination of CMP is unjustified, and sometimes harmful.

**Dietary management of cows’ milk protein allergy**

1. If an infant displays clinical symptoms of CMPA during exclusive breast-feeding, the mother should continue to breast feed, while eliminating from her own diet all foods containing CMP, which must lead to the rapid disappearance of symptoms in the infant within 2–3 weeks. When the symptoms have been resolved, the progressive reintroduction of CMP into the mother’s diet will allow the infant’s tolerance levels to be tested.
2. If clinical symptoms occur during weaning, the best option is to resume exclusive breast-feeding (without any elimination diet in the mother).
3. If the infant is not breast fed or if the mother cannot or no longer wishes to breast feed, the first choice is an extensible hydrolysate (eHF) of CMP.
4. If the eHF fails to achieve the desired result, an AAF is warranted.
5. To date, very few products (Nutramigen® , Pregestimil® , Neocate®, Nutramigen AA®, Blemil Arroz®, Althéra®) have been shown efficient, both in terms of allergy and growth.
6. In the case of anaphylaxis, eosinophilic oesogastroenteropathy, failure to thrive or severe colitis, the use in
the first intention of either an eHF or an AAF is a valid option.
7. Rice protein-based eHF offer an alternative to eHF from animal origin.
8. Soya protein IF can be used after the age of 6 months, after ensuring a good clinical tolerance to soya.
9. The diet must be carefully explained to parents, which includes education about how to read labels. The initial help of a dietitian seems essential.
10. In terms of meat, both beef and veal are tolerated by the majority of children with CMPA.
11. Some products (e.g. medicines for oral use) may contain CMP.
12. Compliance with dietary recommendations, their tolerance and efficacy (disappearance of symptoms and adequate growth) should be regularly assessed.
13. The use of supplements may be required (e.g. for Fe, Ca and vitamin D) during an elimination diet.

Relaxation of the management of CMPA
1. Spontaneous remission of CMPA is the most common outcome during the first 2 to 3 years.
2. The age of recovery varies depending on the child and the type of CMPA, whether it is IgE-mediated or not, with the former being more persistent.
3. Once the child reaches the age of 9–12 months, an OFC is carried out in the hospital ward to assess the development of tolerance and, if possible, to allow for the continued reintroduction of CMP at home.
4. If necessary, repeated OFC allow avoiding the unnecessary prolongation of the elimination diet.
5. The spontaneous recovery from CMPA is not always a complete recovery, and the daily dose of milk/dairy products tolerated by the child may be limited. The current therapeutic options are designed to accelerate the acquisition of tolerance thereof, which seems to be facilitated by repeated exposure to CMP.

Summary of issues and future needs
1. The cost and reimbursement by the health care system of cows’ milk and rice protein-based eHF, AAF, and soya protein-based IF varies from one member-state to another one in the EU. This is very likely to have a strong influence in the management of CMPA, especially in the choice of substitute formulae.
2. Research and regulatory needs. Efforts should be made by governments to help families afford the cost of the disease. Products should be marketed following appropriate testing, analysing both their hypoallergenicity and their adaptation to the clinical situation, such as the role of AAF in allergy to hydrolysates.

Acknowledgements
This review received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. The authors had no personal, commercial, political or
academic conflicts of interest. Financial conflicts of interest (research funding, payment for lectures or travel, consultancies or company support for staff) are reported by C. D. (Danone, Nestlé, Novalac, Sodilac), J. P. C. (Danone, Mead-Johnson, Nestlé, Sodilac), D. d. B. (Danone, Mead-Johnson), A. B. (Danone, Nestlé, Novalac, Sodilac), J. L. B. (Syndalfrans), D. D. (Nestlé), R. H. (Danone), J. G. (Danone), J. P. G. (Danone, Mead-Johnson, Sodilac), O. G. (Danone, Mead-Johnson), M. V. (Danone) and D. T. (Danone, Mead-Johnson, Nestlé). A. B., M. L. F. and D. R. declare that they have no conflicts of interest. The contribution made by each author was as follows: C. D. was the main contributor; J. P. C., D. d. B., M. V. and D. T. were responsible for additional writing and reviewing of the manuscript; A. B., J. L. B., A. B., D. D., M. L. F., J. G., J. P. G., O. G., R. H. and D. R. were involved in the reviewing of the manuscript.

References


Dietary treatment of cows’ milk protein allergy in childhood 337
plasma amino acids, hematology, and trace elements. Am J Clin Nutr 78, 296–301.


